A share price of Cardiff Oncology Inc [CRDF] is currently trading at $1.76, down -3.02%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRDF shares have gain 4.44% over the last week, with a monthly amount glided 14.61%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 29, February 2024, Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update. In a post published today on Yahoo Finance, – First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite -.
From an analyst’s perspective:
Previously, Robert W. Baird started tracking the stock with Outperform rating on December 08, 2021, and set its price target to $19. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $27 on October 22, 2020. Piper Sandler initiated its recommendation with a Overweight and recommended $25 as its price target on October 08, 2020.
Cardiff Oncology Inc experienced fluctuations in its stock price throughout the past year between $0.94 and $2.79. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Cardiff Oncology Inc [NASDAQ: CRDF] shares were valued at $1.76 at the most recent close of the market. An investor can expect a potential return of 297.73% based on the average CRDF price forecast.
Analyzing the CRDF fundamentals
Trailing Twelve Months sales for Cardiff Oncology Inc [NASDAQ:CRDF] were 0.46M which represents 51.61% growth. Gross Profit Margin for this corporation currently stands at -0.21% with Operating Profit Margin at -93.06%, Pretax Profit Margin comes in at -84.97%, and Net Profit Margin reading is -84.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.5 and Total Capital is -0.64. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7000 points at the first support level, and at 1.6350 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8700, and for the 2nd resistance point, it is at 1.9750.
Cardiff Oncology Inc [CRDF] reported earnings per share of -$0.22 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.28/share, meaning a difference of $0.06 and a surprise factor of 21.40%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.25 per share as compared to estimates of -$0.26 per share, a difference of $0.01 representing a surprise of 3.80%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cardiff Oncology Inc [NASDAQ:CRDF] is 9.30. In addition, the Quick Ratio stands at 9.30 and the Cash Ratio stands at 2.07. Considering the valuation of this stock, the price to sales ratio is 171.44, the price to book ratio is 1.01.
Transactions by insiders
Recent insider trading involved PACE GARY W, Director, that happened on Dec 19 when 30000.0 shares were purchased.
